Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure

Summary

This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It contrasts FDA regulatory classifications (Category 2 for BPC-157) with massive underground demand — Telegram communities of 35,000 members funding third-party lab testing, Chinese suppliers shipping enough semaglutide API for over a billion doses, and events like the "Chinese Peptide Rave" where injection techniques are taught in co-working spaces. The piece argues that these scenes collectively expose "regulatory theater" and a deep cultural contradiction in how pharmaceutical access is governed.